Development of BP snapp alternative
Other Transaction IDV Awarded Last action
- Contract number
- W911SR2195000
- Awardee
-
Amneal Pharmaceuticals Of New York, LLC UEI LVEBAQTPN615
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Task orders
- 0
Award facts
- Last date to order
- Not on record
- IDV ceiling
- $3,820,762.00
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
Award details come from SAM.gov/FPDS.
About this IDV
Amneal Pharmaceuticals of New York, LLC was awarded a $3.82 million Other Transaction Indefinite Delivery Vehicle (IDV) by the Department of the Army's Joint Program Executive Office for Chemical and Biological Defense on September 30, 2021. This multiple-award IDV, which carries no set-aside designation, funds the development of alternative medical countermeasures to existing nerve agent pretreatment medications. Specifically, the contract supports the development of alternatives to BP SNAPP (an autoinjector delivery system for nerve agent antidotes) and BOMAN (a pyridostigmine-based nerve agent pretreatment medication). The contract represents the Department of Defense's effort to advance next-generation pharmaceutical solutions for chemical and biological defense capabilities.
The Other Transaction authority mechanism employed for this IDV reflects the Department of Defense's use of flexible acquisition pathways to support innovative pharmaceutical development initiatives outside traditional Federal Acquisition Regulation processes. Amneal's role as prime contractor positions the company to deliver research, development, and potentially prototyping services related to these alternative medical countermeasures. The contract ceiling of approximately $3.82 million provides resources for developmental work that aims to improve upon existing chemical defense medications in terms of efficacy, administration method, side effect profiles, or manufacturing processes. This IDV supports the broader Department of Defense mission to enhance force protection through improved medical countermeasures for chemical and biological threats.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $0 | |
| Other Administrative Action | $101,411 | |
| Other Administrative Action | $1,344,998 | |
| Funding Only Action | $686,344 | |
| Funding Only Action | $342,593 | |
| Supplemental Agreement for work within scope | $350,744 | |
| Original award | $994,672 |
Quick answers
Who was awarded contract W911SR2195000?
W911SR2195000 was awarded to Amneal Pharmaceuticals Of New York, LLC by ACC Aberdeen Proving Ground (Army Contracting Command) on September 30, 2021.
How much is contract W911SR2195000 worth?
W911SR2195000's own ceiling is $3,820,762.
Which agency awarded contract W911SR2195000?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR2195000, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911SR2195000 competed?
The extent of competition for W911SR2195000 was competed.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV